Old DAT and new data: Positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients
| Autor: | Anne Quinquenel, Nadine Varin-Blank, Vincent Levy, Chadi Al Nawakil, Fanny Baran-Marszak, Virginie Eclache, Christine Le Roy, Florence Ajchenbaum-Cymbalista, Rémi Letestu, Alain Delmer, Mohammed Khalloufi, Marouane Boubaya |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty Anemia business.industry Chronic lymphocytic leukemia Hematology medicine.disease Leukemia nervous system Internal medicine Predictive value of tests parasitic diseases mental disorders Immunology Cohort medicine Autoimmune hemolytic anemia business IGHV@ Cohort study |
| Zdroj: | American Journal of Hematology. 90:E5-E8 |
| ISSN: | 0361-8609 |
| DOI: | 10.1002/ajh.23861 |
| Popis: | Only a minority of chronic lymphocytic leukemia (CLL) patients harboring a positive direct antiglobulin test (DAT) will develop autoimmune hemolytic anemia (AIHA). In a single institution cohort of 378 CLL patients, 56 patients (14.8%) had at least one positive DAT during the course of the disease, either at diagnosis or later. We found no relationship between the time of the first positive DAT and overall survival (OS). However, patients with a positive DAT who did not develop AIHA had the same adverse outcome as patients who developed AIHA. Of the patients who were in Binet stage A at diagnosis, those with a positive DAT had a significantly shorter OS, regardless of their IGHV mutational status, however, there was a strong association with VH1-69. By multivariate analysis, a positive DAT was found to be an independent adverse prognostic factor for OS. Thus, DAT represents a strong adverse prognostic factor and its determination should be repeated during follow-up. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text